The blood-brain barrier keeps bad actors like toxins, viruses, and bacteria from entering the brain. But in the case of brain cancer when the danger is already inside, the blood-brain barrier can work against a person’s health by shutting out the medications meant to eliminate the threat. Dr. Sadhana Jackson from the National Institute of Neurological Disorders and Stroke (NINDS) works to figure out ways to selectively get cancer treatments through the blood-brain barrier to treat patients with certain types of brain tumors known as gliomas.
Despite negative consequences and the desire to stop, millions of people with compulsive behaviors can’t break the self-destructive cycles that disrupt their daily lives. Dr. Veronica Alvarez and Dr. Bruno Averbeck from the National Institute of Mental Health run the Center on Compulsive Behaviors (CCB) which brings together NIH scientists to understand what drives these repetitive and often detrimental behaviors. The CCB strives to decipher the neural circuitry that leads to compulsive behaviors in hopes of improving treatments and designing new interventions.
Finding treatments for mental health conditions doesn’t just deal with the people who live with them. Healthy volunteers play a critical part in the science of understanding our brains and behavior. But what qualifies as “healthy” can vary across labs and skew how scientists interpret study results. Dr. Joyce Chung, the Deputy Clinical Director at the National Institute of Mental Health (NIMH), is changing that. She is creating a pool of vetted volunteers to bolster the integrity, efficiency, and safety of mental health research.
There is more to color than meets the eye. According to Dr. Bevil Conway, how we perceive color can inform how our brains receive, interpret, and generate knowledge about the world. Dr. Conway is a visual artist and a neuroscientist at the National Eye Institute. He is working to decode the neural basis of color. In a recent study, his lab mapped how different colors can stimulate different patterns of brain activity.
Ketamine is often thought of as an illicit party drug — something people take for a momentary high. But it wasn’t designed to be a mind-altering drug. Originally, ketamine was developed as anesthetic to relieve temporary pain. And now it seems the drug can provide solace not just from physical distress. At the NIH, Dr. Carlos Zarate is investigating how ketamine can rapidly reduce depressive symptoms in people with treatment-resistant depression or bipolar depression, for whom other options have not helped.
Dr. Peter Bandettini spends a lot of time peering into people's heads. Not because he is clairvoyant, but because he is a biophysicist. Using functional MRI (fMRI), a revolutionary neuroimaging technique he helped pioneer in the '90s, Dr. Bandettini delves into the mysteries of the human brain. He is working to advance fMRI technology to parse out more information about the neural connections that are constantly and spontaneously active even when we think our minds are blank.
The neurons in our brains use both electrical and chemical signals to communicate. When those signals are not generated or interpreted correctly, serious problems can arise. Dr. Jerry Yakel is a neurobiologist studying acetylcholine receptors, which allow neurons to turn signals transmitted using the chemical acetylcholine into electrical messages. Because acetylcholine receptors are found on so many nerve cells, numerous neurological disorders can arise when they fail to work properly, including Alzheimer’s, Parkinson’s, and epilepsy. By studying these receptors, Dr. Yakel’s team hopes to better understand how they contribute to disease, which could eventually lead to therapies for a variety of neurological conditions.
Anybody who observes a person with a neurological illness like Tourette syndrome or schizophrenia can clearly see how these conditions affect behavior. What’s much more difficult to determine is how these ailments relate to changes in the brain. Dr. Armin Raznahan is a child psychiatrist who uses a genetics-first approach and state-of-the-art neuroimaging tools to examine how the size and shape of the brain differ in children and adolescents with neuropsychiatric disorders compared to healthy individuals. His discoveries about these illnesses could ultimately improve our ability to identify and treat people who have them, as well as predict which children might develop them.
